These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33938071)

  • 21. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.
    Corzo JL; Carrillo T; Pedemonte C; Plaza Martin AM; Martín Hurtado S; Dige E; Calderon MA
    J Investig Allergol Clin Immunol; 2014; 24(3):154-61. PubMed ID: 25011352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet.
    Nolte H; Bernstein DI; Sussman GL; Svanholm Fogh B; Lu S; Husøy B; Nelson HS
    J Allergy Clin Immunol Pract; 2018; 6(6):2081-2086.e1. PubMed ID: 29432959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma.
    Mauro M; Boni E; Makri E; Incorvaia C
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1937-43. PubMed ID: 26565665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
    J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation.
    Kito H; Du W; Nakazawa H; Lund K; Ohashi-Doi K
    Biol Pharm Bull; 2019; 42(6):1030-1033. PubMed ID: 31155578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis.
    Demoly P; Okamoto Y; Yang WH; Devillier P; Bergmann KC
    Expert Rev Clin Immunol; 2016 Nov; 12(11):1141-1151. PubMed ID: 27632814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
    Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.
    Bergmann KC; Demoly P; Worm M; Fokkens WJ; Carrillo T; Tabar AI; Nguyen H; Montagut A; Zeldin RK
    J Allergy Clin Immunol; 2014 Jun; 133(6):1608-14.e6. PubMed ID: 24388010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The analysis of Th2 cell subsets in house dust mite allergic rhinitis patients after sublingual immunotherapy].
    Ihara F; Sakurai D; Okamoto Y
    Nihon Yakurigaku Zasshi; 2019; 154(1):12-16. PubMed ID: 31308344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis.
    Guo Y; Li Y; Wang D; Liu Q; Liu Z; Hu L
    Am J Rhinol Allergy; 2017 Jul; 31(4):42-47. PubMed ID: 28716168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.
    Ohashi-Doi K; Kito H; Du W; Nakazawa H; Ipsen H; Gudmann P; Lund K
    Int Arch Allergy Immunol; 2017; 174(1):26-34. PubMed ID: 28950271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of house dust mite allergy.
    Yang L; Zhu R
    Hum Vaccin Immunother; 2017 Oct; 13(10):2390-2396. PubMed ID: 28853977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.
    Zieglmayer P; Nolte H; Nelson HS; Bernstein DI; Kaur A; Jacobi H; Lemell P; Schmutz R; Zieglmayer R; Horak F
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):690-696.e1. PubMed ID: 27979028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis.
    Jordakieva G; Kundi M; Lemell P; Zieglmayer R; Zieglmayer P; Godnic-Cvar J; Jensen-Jarolim E
    Sci Rep; 2017 May; 7(1):2555. PubMed ID: 28566688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial.
    Demoly P; Corren J; Creticos P; De Blay F; Gevaert P; Hellings P; Kowal K; Le Gall M; Nenasheva N; Passalacqua G; Pfaar O; Tortajada-Girbés M; Vidal C; Worm M; Casale TB
    J Allergy Clin Immunol; 2021 Mar; 147(3):1020-1030.e10. PubMed ID: 32890575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. House Dust Mite-Specific Sublingual Immunotherapy Prevents the Development of Allergic Inflammation in a Mouse Model of Experimental Asthma.
    Hagner S; Rask C; Brimnes J; Andersen PS; Raifer H; Renz H; Garn H
    Int Arch Allergy Immunol; 2016; 170(1):22-34. PubMed ID: 27287860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children.
    Masuyama K; Okamoto Y; Okamiya K; Azuma R; Fujinami T; Riis B; Ohashi-Doi K; Natsui K; Imai T; Okubo K
    Allergy; 2018 Dec; 73(12):2352-2363. PubMed ID: 30043449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy.
    Boonpiyathad T; Sokolowska M; Morita H; Rückert B; Kast JI; Wawrzyniak M; Sangasapaviliya A; Pradubpongsa P; Fuengthong R; Thantiworasit P; Sirivichayakul S; Kwok WW; Ruxrungtham K; Akdis M; Akdis CA
    Allergy; 2019 May; 74(5):976-985. PubMed ID: 30485456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.